These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 17520770)

  • 1. Use of ozone-depleting substances; removal of essential use designations; confirmation of effective date. Direct final rule; confirmation of effective date.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Apr; 72(81):20942. PubMed ID: 17520770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of ozone-depleting substances; removal of essential-use designations. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Apr; 70(63):17167-92. PubMed ID: 15806739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of ozone-depleting substances; removal of essential-use designation (flunisolide, etc.). Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2010 Apr; 75(71):19213-41. PubMed ID: 20391646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revision of the requirements for live vaccine processing; confirmation of effective date. Direct final rule; confirmation of effective date.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Mar; 73(46):12262-3. PubMed ID: 18464339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conforming regulations regarding removal of section 507 of the Federal Food, Drug, and Cosmetic Act; confirmation of effective date. Food and Drug Administration, HHS. Direct final rule; confirmation of effective date.
    Fed Regist; 1999 May; 64(94):26657. PubMed ID: 10558515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revisions to the requirements applicable to blood, blood components and source plasma; confirmation of effective date and technical amendment. Direct final rule; confirmation of effective date and technical amendment.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Feb; 73(27):7463-4. PubMed ID: 18389917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; policies, requirements, and administrative procedures; delay of effective date. Final rule; delay of effective date.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Feb; 69(35):8105-7. PubMed ID: 14997866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
    Balkissoon R; Make B
    COPD; 2008 Aug; 5(4):221-7. PubMed ID: 18671147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Final rule on albuterol inhalers.
    FDA Consum; 2005; 39(4):3. PubMed ID: 16255065
    [No Abstract]   [Full Text] [Related]  

  • 10. Economics of "essential use exemptions" for metered-dose inhalers under the Montreal Protocol.
    DeCanio SJ; Norman CS
    J Environ Manage; 2007 Oct; 85(1):1-8. PubMed ID: 16982135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revision of requirements applicable to albumin (human), plasma protein fraction (human), and immune globulin (human); confirmation in part and technical amendment. Food and Drug Administration, HHS. Direct final rule; confirmation in part and technical amendment.
    Fed Regist; 2000 Mar; 65(50):13678-9. PubMed ID: 11010647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Ozone-Depleting Substances. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2016 Oct; 81(207):74298-302. PubMed ID: 27905700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution of blood derivatives by registered blood establishments that qualify as health care entities; Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; delay of applicability date. Final rule; delay of applicability date.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Nov; 71(218):66108-9. PubMed ID: 17099971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
    Lindberg A; Szalai Z; Pullerits T; Radeczky E
    Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use; partial final rule for combination drug products containing a bronchodilator. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2001 Sep; 66(188):49276-8. PubMed ID: 11758596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revisions to the requirements applicable to blood, blood components, and source plasma; confirmation in part and technical amendment. Food and Drug Administration, HHS. Direct final rule; confirmation in part and technical amendment.
    Fed Regist; 2001 Jan; 66(7):1834-7. PubMed ID: 11503754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does measuring BHR add to guideline derived clinical measures in determining treatment for patients with persistent asthma?
    Koenig SM; Murray JJ; Wolfe J; Andersen L; Yancey S; Prillaman B; Stauffer J; Dorinsky P
    Respir Med; 2008 May; 102(5):665-73. PubMed ID: 18328683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skin protectant drug products for over-the-counter human use; final monograph. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(107):33362-81. PubMed ID: 12785379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revisions to the general safety test requirements for biological products--FDA. Direct final rule: confirmation in part and withdrawal in part.
    Fed Regist; 1998 Aug; 63(150):41718. PubMed ID: 10181723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective claims study of fluticasone propionate/salmeterol fixed-dose combination use as initial asthma controller therapy in children despite guideline recommendations.
    Friedman HS; Eid NS; Crespi S; Wilcox TK; Reardon G
    Clin Ther; 2009 May; 31(5):1056-63. PubMed ID: 19539106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.